Esketamine alleviates depressive-like behavior in neuropathic pain mice through the METTL3-GluA1 pathway

• DOI: 10.1007/s10565-024-09975-1
• Publication Date: 2025-01-29T01:36:10Z
• Authors: Xiaoming Ji; Zhimin Huang; Chenming Zhou; Yu Wang; Dongliang Geng; Guoliang Zhang; Yunxiao Kang; Rui Cui; Jinyang Wang; Tianyun Zhang

Esketamine, a newly developed antidepressant, is the subject of this research which seeks to explore its impact on depressive symptoms in neuropathic pain mice and potential molecular mechanisms involved. Through transcriptome sequencing bioinformatics analysis combined with vivo studies, it was identified that esketamine markedly boosts levels m6A methyltransferase METTL3 AMPA receptor GluA1 subunit. Esketamine activates METTL3, allowing bind mRNA, promoting modification, thereby enhancing expression at synapses. mechanism, may reduce depressive-like behavior mice, providing new insights into applications novel therapeutic avenues for behavior.